---
title: 'Lomitapide for the treatment of paediatric patients with homozygous familial
  hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label,
  multicentre, phase 3 study'
date: '2024-10-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39426393/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241020192058&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Homozygous familial hypercholesterolaemia (HoFH) is a rare
  inherited disorder characterised by extremely high concentrations of LDL cholesterol,
  leading to early-onset atherosclerosis. Lomitapide is an orally administered microsomal
  triglyceride transfer protein (MTP) inhibitor that effectively lowers LDL cholesterol
  and is approved for adults with HoFH. We aimed to investigate the efficacy and safety
  of lomitapide in paediatric patients with HoFH receiving ...'
disable_comments: true
---
BACKGROUND: Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder characterised by extremely high concentrations of LDL cholesterol, leading to early-onset atherosclerosis. Lomitapide is an orally administered microsomal triglyceride transfer protein (MTP) inhibitor that effectively lowers LDL cholesterol and is approved for adults with HoFH. We aimed to investigate the efficacy and safety of lomitapide in paediatric patients with HoFH receiving ...